Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
Retrieved on:
Friday, April 1, 2022
Disease, Private Securities Litigation Reform Act, Regulation, Biomarker, LinkedIn, Microfluidics, Transaction, Marketing, Forward-looking statement, Immunotherapy, Viking Global Investors, Growth, Coronavirus, Board, Centerview Partners, Â, Paul, Weiss, Rifkind, Wharton & Garrison, SEC, Biotechnology, Research, Cancer, Health, Failure, U.S. Securities and Exchange Commission, Communication, Jefferies Group, Professional corporation, Government, Quality of life, LLC, CyTOF, Industry, Technology, Director, Twitter, Disclosure, Nasdaq, Wilson Sonsini Goodrich & Rosati, GLOBE, Regulation Fair Disclosure, Eye, SAN, Annual report, FDA, Social media, Security (finance), Renewable energy, Financial adviser, Joseph C. Casdin, Vikings, Fluidigm, Facebook
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (Casdin) and Viking Global Investors LP (Viking).
Key Points:
- SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (Casdin) and Viking Global Investors LP (Viking).
- Under the terms of the agreement, Casdin and Viking will purchase $225 million in aggregate principal amount of convertible preferred shares.
- Jefferies LLC is serving as financial advisor to Fluidigm and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal advisor.
- Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.